The use of opioids in fibromyalgia

International Journal of Rheumatic Diseases

Volumn 14, Issue 1, 2011, Pages 6-11

  Ngian, Gene Siew ^a   Guymer, Emma K ^a   Littlejohn, Geoffrey O ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Analgesics; Drug therapy; Fibromyalgia; Opioids; Tramadol

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BUPRENORPHINE; CALCIUM; DULOXETINE; GABAPENTIN; IBUPROFEN; METHADONE; MILNACIPRAN; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PRAMIPEXOLE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TAPENTADOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYGDALOID NUCLEUS; ANALGESIA; ANTERIOR CINGULATE; ANXIETY; CALCIUM TRANSPORT; CHRONIC PAIN; CONSTIPATION; DRUG EFFICACY; DRUG USE; EUPHORIA; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HYPERALGESIA; LOW BACK PAIN; MENTAL CLOUDING; MENTAL DISEASE; MESENCEPHALON; MOOD DISORDER; NAUSEA; NOCICEPTION; NUCLEUS ACCUMBENS; OPIATE ADDICTION; OPIOID INDUCED HYPERALGESIA; PAIN; PATHOPHYSIOLOGY; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SEDATION; SENSITIZATION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VISUAL ANALOG SCALE; VOMITING;

ANALGESICS, OPIOID; EVIDENCE-BASED MEDICINE; FIBROMYALGIA; HUMANS; NALTREXONE; PAIN; PRACTICE GUIDELINES AS TOPIC; TRAMADOL; TREATMENT FAILURE;

EID: 79751480572     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2010.01567.x     Document Type: Review

References (47)

1. Weir PT, Harlan GA, Nkoy FL, et al. (2006) The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 12, 124-8.
2. Wolfe F, Smythe HA, Yunus MB, et al. (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33, 160-72.
3. Wolfe F, Clauw D, Fitzcharles MA, et al. (2010) The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 65, 600-10.
4. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38, 19-28.
5. Sicras-Mainar A, Rejas J, Navarro R, et al. (2009) Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 11, R54.
6. Hoffman DL, Dukes EM (2008) The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 62, 115-26.
7. Littlejohn GO (2004) Balanced treatments for fibromyalgia. Arthritis Rheum 50, 2725-9.
8. Williams DA, Clauw DJ (2009) Understanding fibromyalgia: lessons from the broader pain research community. J Pain 10, 777-91.
9. Gibson SJ, Littlejohn GO, Gorman MM, Helme RD, Granges G (1994) Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain 58, 185-93.
10. Gracely RH, Petzke F, Wolf JM, Clauw DJ (2002) Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46, 1333-43.
11. Jensen KB, Kosek E, Petzke F, et al. (2009) Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain 144, 95-100.
12. Usui C, Hatta K, Doi N, et al. (2010) Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin. Arthritis Res Ther 12, R64.
13. Napadow V, Lacount L, Park K, As-Sanie S, Clauw DJ, Harris RE (2010) Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum 62, 2545-55.
14. Russell IJ, Mease PJ, Smith TR, et al. (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136, 432-44.
15. Mease PJ, Clauw DJ, Gendreau RM, et al. (2009) The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 36, 398-409.
16. Crofford LJ, Rowbotham MC, Mease PJ, et al. (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52, 1264-73.
17. Arnold LM, Goldenberg DL, Stanford SB, et al. (2007) Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 56, 1336-44.
18. Russell IJ, Perkins AT, Michalek JE (2009) Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 60, 299-309.
19. Holman AJ, Myers RR (2005) A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52, 2495-505.
20. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ (2010) Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 149, 360-4.
21. Carville SF, Arendt-Nielsen S, Bliddal H, et al. (2008) EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 67, 536-41.
22. Goldenberg DL, Burckhardt C, Crofford L (2004) Management of fibromyalgia syndrome. JAMA 292, 2388-95.
23. Goldenberg DL, Felson DT, Dinerman H (1986) A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 29, 1371-7.
24. Wolfe F, Zhao S, Lane N (2000) Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1, 799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 43, 378-85.
25. Chou R, Fanciullo GJ, Fine PG, et al. (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10, 113-30.
26. Woodcock J (2009) A difficult balance--pain management, drug safety, and the FDA. N Engl J Med 361, 2105-7.
27. Leong M, Murnion B, Haber PS (2009) Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 39, 676-81.
28. Wolfe F, Anderson J, Harkness D, et al. (1997) A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 40, 1560-70.
29. Berger A. Patterns of use of opioids in patients with fibromyalgia. In: EULAR; 2009:SAT0461.
30. Clauw DJ (2009) Fibromyalgia: an overview. Am J Med 122, S3-13.
31. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M (1995) Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 24, 360-5.
32. Kemple KL, Smith G, Wong-Ngan J (2003) Opioid therapy in fibromyalgia: a fouryear prospective evaluation of therapy selection, efficacy, and predictions of outcome. Arthritis Rheum 48, S88.
33. Enno F (2008) Opioids in Medicine: A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Clinical Pain States. Springer, Dordrecht.
34. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK (2007) Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 27, 10000-6.
35. Yunus MB, Denko CW, Masi AT (1986) Serum beta-endorphin in primary fibromyalgia syndrome: a controlled study. J Rheumatol 13, 183-6.
36. Hall S, Littlejohn GO, Gethwa J, Copolov D (1983) Plasma beta-endorphin levels in fibrositis. Arthritis Rheum 26, 539.
37. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ (2004) Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord 5, 48.
38. Crofford LJ (2010) Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nat Rev Rheumatol 6, 191-7.
39. Chu LF, Angst MS, Clark D (2008) Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 24, 479-96.
40. Koppert W, Ihmsen H, Korber N, et al. (2005) Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 118, 15-22.
41. Biasi G, Manca S, Manganelli S, Marcolongo R (1998) Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 18, 13-9.
42. Bennett RM, Kamin M, Karim R, Rosenthal N (2003) Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 114, 537-45.
43. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR (2005) Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 53, 519-27.
44. Tzschentke TM, Christoph T, Kogel B, et al. (2007) (-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 323, 265-76.
45. Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C (2009) Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90days: a randomized, double-blind study. Curr Med Res Opin 25, 1095-104.
46. Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J (2009) A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 25, 1551-61.
47. Younger J, Mackey S (2009) Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 10, 663-72.